Cargando…

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462947/ https://www.ncbi.nlm.nih.gov/pubmed/36092851 http://dx.doi.org/10.2147/JBM.S388118

Ejemplares similares

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma
por: Tanaka, Hiroaki, et al.
Publicado: (2018)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study
por: Tsukada, Nobuhiro, et al.
Publicado: (2021)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India
por: Das, Soumya, et al.
Publicado: (2022)

Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
por: Moreb, Jan S., et al.
Publicado: (2011)

Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
por: Ray, Gopal Krushna, et al.
Publicado: (2021)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

CORRIGENDUM to “Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?”
Publicado: (2021)

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2020)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
por: Parody, Rocío, et al.
Publicado: (2020)

Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2021)

Corrigendum to “Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children”
por: Vázquez Meraz, José Eugenio, et al.
Publicado: (2016)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Biosimilar G-CSF Based Mobilization of Peripheral Blood Hematopoietic Stem Cells for Autologous and Allogeneic Stem Cell Transplantation
por: Schmitt, Michael, et al.
Publicado: (2014)

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Eplin, Dwight D., et al.
Publicado: (2019)

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review
por: Yamamoto, Eiko, et al.
Publicado: (2017)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis
por: Yang, Xiaoyang, et al.
Publicado: (2019)

Corrigendum to “Evaluation of Novel Stereotactic Cannula for Stem Cell Transplantation against Central Nervous System Disease”
por: Kawabori, Masahito, et al.
Publicado: (2021)

Corrigendum to “The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes”
por: Napoli, Nicola, et al.
Publicado: (2017)

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells
por: Orio, Francesco, et al.
Publicado: (2014)

SHIPi Enhances Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Fernandes, Sandra, et al.
Publicado: (2015)

Editorial: Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy
por: Sharma, Nidhi, et al.
Publicado: (2023)

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas
por: Reimer, Peter
Publicado: (2010)

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
por: Visram, Alissa, et al.
Publicado: (2018)

Clinical Allogeneic and Autologous Islet Cell Transplantation: Update
por: Matsumoto, Shinichi
Publicado: (2011)

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study
por: de Greef, Georgine E., et al.
Publicado: (2018)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Corrigendum to “Plasmatic Membrane Expression of Adhesion Molecules in Human Cardiac Progenitor/Stem Cells Might Explain Their Superior Cell Engraftment after Cell Transplantation”
por: Ontoria-Oviedo, Imelda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jsti0ooq9n142s7atos9nqusn9